Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Allopurinol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BCX4208 placebo + Allopurinol placebo | PLACEBO_COMPARATOR | Administered daily for 21 days. |
| BCX4208 placebo + Allopurinol 100mg | ACTIVE_COMPARATOR | Administered daily for 21 days. |
| BCX4208 placebo + Allopurinol 200 mg | ACTIVE_COMPARATOR | Administered daily for 21 days. |
| BCX4208 Placebo + Allopurinol 300 mg | ACTIVE_COMPARATOR | Administered daily for 21 days. |
| BCX4208 20 mg + Allopurinol Placebo | EXPERIMENTAL | Administered daily for 21 days. |
| BCX4208 20 mg + Allopurinol 100 mg | EXPERIMENTAL | Administered daily for 21 days. |
| BCX4208 20 mg + Allopurinol 200 mg | EXPERIMENTAL | Administered daily for 21 days. |
| BCX4208 20 mg + Allopurinol 300 mg | EXPERIMENTAL | Administered daily for 21 days. |
| BCX4208 40 mg + Allopurinol placebo | EXPERIMENTAL | Administered daily for 21 days. |
| BCX4208 40 mg + Allopurinol 100 mg | EXPERIMENTAL | Administered daily for 21 days. |
| BCX4208 40 mg + Allopurinol 200 mg | EXPERIMENTAL | Administered daily for 21 days. |
| BCX4208 40 mg + Allopurinol 300 mg | EXPERIMENTAL | Administered daily for 21 days. |
| BCX4208 80 mg + Allopurinol Placebo | EXPERIMENTAL | Administered daily for 21 days. |
| BCX4208 80 mg + Allopurinol 100 mg | EXPERIMENTAL | Administered daily for 21 days. |
| BCX4208 80 mg + Allopurinol 200 mg | EXPERIMENTAL | Administered daily for 21 days. |
| BCX4208 80 mg + Allopurinol 300 mg | EXPERIMENTAL | Administered daily for 21 days. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Administered daily for 21 days |
| Allopurinol | DRUG | Administered daily for 21 days. |
| BCX4208 | DRUG | Administered daily for 21 days. |
Inclusion Criteria: 1. Age ≥18 to \<70 years, with screening sUA \> 8.0 mg/dL. 2. Diagnosis of gout according to the criteria of the American Rheumatism Association (1977). 3. Be willing and able to take colchicine 0.6 mg per day or naproxen 250 mg twice daily (with proton pump inhibitor if needed)...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Amgen Inc. | AMGN | 1 | PHASE3 | Pegloticase, Methotrexate |
| Protalix BioTherapeutics, Inc. (DE) | PLX | 1 | PHASE2 | PRX-115, Methotrexate |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 1 | PHASE1 | NNC4004-0002 |
| TJ Biopharma Co., Ltd. | IMAB | 1 | PHASE2 | Plonmarlimab, Compound betamethasone |
| Sunshine Biopharma Incorporated | SBFM | 1 | PHASE1 | Pegylated Recombinant Candida Utilis Uricase |
Allopurinol is a small molecule being studied for the treatment of gout. It is a metabolic therapeutic that is being evaluated in combination with another investigational drug to lower serum uric acid levels. The drug is currently in Phase 2 clinical development for this indication.
Allopurinol is being developed by BioCryst Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BCRX. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with gout.
Allopurinol is in Phase 2 clinical development for the treatment of gout. It is an investigational drug and has not been approved by regulatory authorities. A Phase 2 clinical trial has been completed to evaluate its serum uric acid-lowering activity, safety, and pharmacokinetic interaction.
Allopurinol has been studied in one completed Phase 2 clinical trial, identified as NCT01129648. This randomized, double-blind, placebo-controlled study enrolled 87 participants with gout in the United States to evaluate the serum uric acid-lowering activity, safety, and pharmacokinetic interaction of oral BCX4208 and Allopurinol.
No, Allopurinol is not the same as BCX4208. Allopurinol is the drug being studied, while BCX4208 is a separate investigational drug that was administered in combination with Allopurinol in the clinical trial. The study evaluated the interaction and combined effects of both drugs in subjects with gout.